Charles Q. Huang
VP of Global Business Development
Sundia MediTech Company, Ltd., Shanghai, China
Email:, Web:
Charles Huang joined Sundia in March 2008, a top Chinese CRO that provides fully-integrated drug discovery and development services to its worldwide clients. Charles is currently Vice President of Global Business Development who is responsible for all US and Canadian markets.
Prior to Sundia, Charles served as president of Amnova, a pharmaceutical consultant firm in US. He worked for 15 year as medicinal chemist at Neurocrine Bioscience Inc (NBI), Johnson & Johnson and Amylin, including 4-year part-time experience on CRO project management and new market BD for advanced clinic candidate. During his tenure at NBI, Charles made significant contributions to CRF1, CRF-BP, and Insomia projects, all resulting major collaborations with Johnson and Johnson, Eli Lilly and Pfizer. He is co-author for 22 publications, 10 presentations and 12 US patents.
Charles graduated with BS in Polymer Chemistry from University of Science and Technology of China (USTC) in 1989, and obtained his MS in organic chemistry at California State University at Northridge. Besides his science and business career in drug discovery, Charles founded a non-profit 501c3 charitable organization in 2004 where he served as President (2004-2008) and Chair of Board (2008-2010).